fairplus stamp

IMIDIA Cohort 1

Primary Purpose: Pancreatic tissue and blood samples from metabolically phenotyped pancreatectomised patients to identify transcriptomic changes in type 2 diabetic islets
Study Types: identification of diagnostic biomarkers for treatment and monitoring in diabetes
Description of Cohorts: IMIDIA cohort 1 participants
Informed Consent Given?: True
Multi-center Study?: True
Study characteristics: Specimen collection protocol Total pancreatectomy, Partial pancreatectomy

Organisms: Homo sapiens
Number of subjects: 415
Diseases: type I diabetes type II diabetes disease free impaired glucose tolerance type III diabetes impaired fasting glycaemia
Sample Sources: tissue sample
Type of Samples Collected: pancreas RNA pancreatic islet blood DNA

Cohort characteristics: age at enrollment 23-86 year

height 1.48-2.04 meter

weight 38-142 kg

BMI 13.96-44.59 kg/m2

sex 233 male, 182 female

diabetes status 122 type II diabetes, 104 type III diabetes, 81 impaired glucose tolerance, 1 type I diabetes, 17 impaired fasting glycaemia, 59 non-diabetic

blood glucose in oral glucose tolerance test (0h) 0.07-12.26 mmol/L

blood glucose in oral glucose tolerance test (1h) 4.53-19.33 mmol/L

blood glucose in oral glucose tolerance test (2h) 2.44-21.50 mmol/L

Hemoglobin A1C 3.60-13.50 %

HOMA1-IR Index 0.00-61.00

HOMA1-B Index 0.20-960.00

HOMA1-S Index 0.03-277.43

Fasting Insulin IP 0.11-480.00 pmol/L

Fasting Insulin 0.02-69.12

Fasting Glucose IP 2.68-33.32 mmol/L

Fasting Insulin in serum 0.01-0.33 nmol/L

Insulin in serum (1h)) 0.03-2.13 nmol/L

Insulin in serum (2h) 0.03-2.91 nmol/L

Fasting C-peptide in serum 0.02-3.59

C-peptide in serum (1h) 0.62-8.02

C-peptide in serum (2h) 0.90-8.04

Fasting Proinsulin in serum 0.06-32.90 pmol/L

Proinsulin in serum (1h) 1.70-82.20 pmol/L

Proinsulin in serum (2h) 1.80-125.60 pmol/L

potassium in serum 0.94-5.75 mmol/L

magnesium in serum 0.44-4.82 mmol/L